{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:15:14Z","timestamp":1789467314114,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ac\u0131badem University"},{"id":[{"id":"https:\/\/ror.org\/01rp2a061","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Objectives: Hepatocellular carcinoma (HCC) is a disease with an increasing incidence. Liver transplantation (LT) represents the sole curative treatment option. Downstaging (DS) therapy represents an option in selecting suitable candidates for transplantation who initially have tumors exceeding the MC. Consequently, patients undergoing DS for MC have demonstrated comparable survival rates to those who initially met the MC. Degradable starch microspheres with transcatheter arterial chemoembolization (DSM-TACE), a type of TACE, have also been recently introduced in clinical practice. Methods: This retrospective study encompassed 200 consecutive adult patients who underwent living-donor LT for HCC and cirrhosis at two different centers from March 2012 to December 2023. We aimed to compare long-term overall survival (OS) and recurrence-free survival (RFS) among patients with HCC who met the DSM-TACE criteria for MC following diagnosis, those initially within MC, and those outside MC following diagnosis. Results: The OS rate in the MC group was statistically comparable to that in the DS and beyond the MC groups. The MC and DS groups exhibited comparable long-term RFS rates. However, the MC and DS groups showed significantly better RFS rates than the beyond the MC group. Microvascular invasion (MVI), tumor size and number, and the beyond the MC group were identified as significant recurrence risk factors, whereas MVI alone was an independent prognostic factor. Conclusions: Our results showed good long-term OS and RFS in HCC patients following LDLT after staging into MC with DSM-TACE. Additionally, we achieved a more acceptable survival rate compared to other treatments in the group that underwent MC staging after DS.<\/jats:p>","DOI":"10.3390\/life16091532","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:16:48Z","timestamp":1789460208000},"page":"1532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Long-Term Outcomes of Living-Donor Liver Transplantation in Hepatocellular Carcinoma Based on the Milan Criteria After Downstaging According to Degradable Starch Microspheres with Transcatheter Arterial Chemoembolization"],"prefix":"10.3390","volume":"16","author":[{"given":"Umut","family":"T\u00fcys\u00fcz","sequence":"first","affiliation":[{"name":"Department of General Surgery, Sar\u0131yer Hamidiye EtfalTraining and Research Hospital, Istanbul 34453, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2344-7783","authenticated-orcid":false,"given":"Tonguc Utku","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of General Surgery, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul 34303, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam Bak\u0131r","family":"Bat\u0131","sequence":"additional","affiliation":[{"name":"Department of Liver transplantation, Bursa Ac\u0131badem Hospital, Bursa 16210, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u015f\u0131l","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Vocational School of Health Services, Medical \u0130maging Techniques, Acibadem Mehmet Ali Aydinlar University, Istanbul 34303,Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/hbsn-21-350","article-title":"Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: A meta-analysis of 18,421 patients","volume":"11","author":"Koh","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma After tumour downstaging (XXL): A randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101234","DOI":"10.1016\/j.tranon.2021.101234","article-title":"Commentary: A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria","volume":"14","author":"Ling","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00432-020-03215-9","article-title":"Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis","volume":"146","author":"Bauschke","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"570962","DOI":"10.2147\/JHC.S570962","article-title":"Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy","volume":"13","author":"Wang","year":"2026","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for hepatocellular carcinoma. working group report from the ILTS Transplant Oncology Consensus Conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: A systematic review and pooled analysis","volume":"21","author":"Parikh","year":"2015","journal-title":"Liver Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_12","unstructured":"National Comprehensive Cancer Network (NCCN) (2020, January 17). NCCN Clinical Practice Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.14218\/JCTH.2016.00058","article-title":"Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels","volume":"4","author":"Schicho","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00270-019-02364-w","article-title":"Transarterial chemoembolisation (TACE) with degradable starch microspheres (DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): Safety and efficacy","volume":"43","author":"Gross","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"634087","DOI":"10.3389\/fphar.2021.634087","article-title":"Safety and Ef cacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9","volume":"12","author":"Minici","year":"2021","journal-title":"Front Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3325\/cmj.2022.63.317","article-title":"Liver transplantation in hepatocellular carcinoma\u2014Should we perform downstaging?","volume":"63","year":"2022","journal-title":"Croat. Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.30879","article-title":"National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time","volume":"71","author":"Mehta","year":"2020","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies","volume":"21","author":"Tan","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s12072-023-10511-2","article-title":"Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation","volume":"17","author":"Qu","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within MC","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2015.01.023","article-title":"Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?","volume":"63","author":"Allard","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1038\/s41598-021-92976-5","article-title":"Liver transplantation for hepatocellular carcinoma using grafts from uncontrolled circulatory death donation","volume":"11","author":"Nutu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic Response to Pretransplant Locoregional Therapy Is Predictive of Patient Outcome after Liver Transplantation for Hepatocellular Carcinoma: Analysis from the US Multicenter HCC Transplant Consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.3748\/wjg.v25.i37.5687","article-title":"Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging","volume":"25","author":"Affonso","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"T\u0131rnova, I., and Kanmaz, T. (2025). Liver transplantation for HCC within and beyond Milan Criteria: Single center experience with literature review. Front. Surg., 12.","DOI":"10.3389\/fsurg.2025.1594361"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.transproceed.2015.12.078","article-title":"Drug- Eluting Bead Transarterial Chemoembolization as Bridge Therapy for Hepatocellular Carcinoma Before Living-Donor Liver Transplantation","volume":"48","author":"Yu","year":"2016","journal-title":"Transplant. Proc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/JS9.0000000000000325","article-title":"Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: A multicenter retrospective cohort study from a hepatitis B virus-endemic area","volume":"109","author":"Xu","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tang, Z., Li, X., Zheng, Y., Liu, J., Liu, C., and Li, X. (2024). The role of competing endogenous RNA network in the development of hepatocellular carcinoma: Potential therapeutic targets. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1341999"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4240\/wjgs.v16.i2.554","article-title":"Comparative effectiveness of several adjuvant therapies after hepatectomy for hepatocellular carcinoma patients with microvascular invasion","volume":"16","author":"Pei","year":"2024","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: Updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:44:51Z","timestamp":1789461891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091532"],"URL":"https:\/\/doi.org\/10.3390\/life16091532","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}